Nutriband Inc. Achieves Key Milestone in Development of Abuse-Deterrent Fentanyl Patch

Nutriband Inc. (NASDAQ: NTRB), in collaboration with Kindeva Drug Delivery, has successfully completed the commercial-scale manufacturing process for AVERSA™ Fentanyl, a pioneering abuse-deterrent fentanyl transdermal system. This milestone is a critical step in the path to FDA approval, offering a potential solution to the opioid crisis by mitigating the abuse potential of fentanyl, a synthetic opioid known for its high risk of addiction and overdose.

The development of AVERSA™ Fentanyl is timely, as the opioid crisis continues to pose significant public health challenges worldwide. The technology behind AVERSA™ is protected by international patents and represents a significant advancement in the field of pain management. By incorporating abuse-deterrent properties, AVERSA™ aims to provide a safer option for patients requiring potent pain relief, while addressing the concerns of healthcare providers and regulators regarding opioid abuse.

Analysts have taken note of Nutriband's progress, with an updated report raising the company's price target to $15.00 and reiterating an Outperform rating. The report highlights the favorable trial pathway and strong execution by Nutriband and Kindeva as key factors in the optimistic outlook. Furthermore, Nutriband's recent inclusion in the Russel Indexes enhances its profile and credibility within the investment community, signaling growing recognition of its potential to make a meaningful impact in the pharmaceutical industry.

The completion of commercial-scale manufacturing for AVERSA™ Fentanyl not only marks a significant achievement for Nutriband and Kindeva but also underscores the importance of innovation in addressing the opioid crisis. As the product moves closer to FDA approval, the healthcare industry watches closely, anticipating the potential of AVERSA™ to redefine standards for opioid safety and efficacy.